



June 12, 2012

Origin Trial Participant

Dear Participant:

Thank you for participating in the **Outcome Reduction with Initial Glargine Intervention (ORIGIN)** Trial. Your involvement in the trial for the last eight years has helped answer two important medical questions: does insulin glargine reduce the risk of heart attack and stroke; and do omega-3 fatty acid supplements reduce the risk of death from heart disease?

You are one of 12,537 people with diabetes or pre-diabetes from around the world who participated in this trial. You may have taken insulin glargine and you also took either an omega-3 fatty acid supplement or placebo.

The study results showed that taking insulin glargine neither increased nor decreased your risk of developing a heart attack or stroke. There was, however, better blood sugar control and less onset of new diabetes for people who took insulin. The results also showed that taking omega-3 fatty acid supplements did not change the risk of dying from heart disease.

Based on these results, we know more about how best to use these common drugs. We could not have done this without your participation. There is still a question if taking these drugs as long as you did had a longer term effect on your health. To help us to answer this question, you are invited to participate in the ORIGINALE study, an extension of the ORIGIN trial. The ORIGINALE study has been designed to collect information about your health for the next two years. Visits will occur once every year and you can continue to take your current medications. A researcher from my site will contact you with more information about this study.

If you have any questions with regards to this information please contact your site contact.

Sincerely,

Principal Investigator